Quantum BioPharma (NASDAQ: QNTM) was featured in a Men’s Fitness article by Lakshan Weeraratne examining clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The article highlights findings from a company-sponsored, placebo-controlled study involving 26 healthy adults, with 24 completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo.
The Men’s Fitness article also emphasized the study’s limitations, including its small sample size, company sponsorship and mixed results across broader measures of hangover severity and cognitive impairment. While the findings suggest potential benefits for certain alcohol recovery measures, the article noted that larger, independent clinical trials are needed to confirm the results. It also cautioned that increased alertness does not indicate sobriety or fitness to drive.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer